Regeneron sinks as Phase 3 skin cancer treatment trial fails (opens in new tab)

Covers Publicis to acquire LiveRamp to accelerate data co-creation for smarter agents

The company faces a wave of price target cuts and a steep stock decline following the late-stage clinical trial failure of its experimental melanoma combination therapy.

Read the original article